Content about Par Pharmaceutical

August 3, 2011

Par Pharmaceutical had sales of $224.2 million and profits of $9.05 million during second quarter 2011, the drug maker said Wednesday.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical had sales of $224.2 million and profits of $9.05 million during second quarter 2011, the drug maker said Wednesday.

These compared with respective sales and second-quarter profits of $255.5 million and $18.4 million in second quarter 2010.

For the first six months of fiscal year 2011, the company had sales of $435.8 million and a loss of $99.9 million, compared with $537 million in sales and profits of $44.7 million during the first six months of 2010.

 

July 5, 2011

As part of a strategic assessment, generic drug maker Par Pharmaceutical is set to restructure its branded division.

WOODCLIFF LAKE, N.J. — As part of a strategic assessment, generic drug maker Par Pharmaceutical is set to restructure its branded division.

The company said last week that its restructuring of Strativa Pharmaceuticals will result in a reduced workforce, prompting one-time noncash charges in the second quarter in addition to severance costs, although Par said the restructuring will generate expense savings in the $8 to $12 million range for the remainder of the year.

April 4, 2011

PL Developments on Monday announced that it has acquired the exclusive rights to sell and distribute store-brand over-the-counter versions of omeprazole sodium bicarbonate capsules, the generic version of Merck’s Zegerid OTC.

WESTBURY, N.Y. — PL Developments on Monday announced that it has acquired the exclusive rights to sell and distribute store-brand over-the-counter versions of omeprazole sodium bicarbonate capsules, the generic version of Merck’s Zegerid OTC.

Par Pharmaceutical currently has approval for the prescription product and has filed for the OTC version. Upon FDA approval and upon favorable resolution of intellectual property litigation, PL Developments will begin marketing the new store-brand proton-pump inhibitor, the company stated.

January 4, 2011

Par Pharmaceutical has started shipping a generic version of a hypertension drug, the company said Monday.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical has started shipping a generic version of a hypertension drug, the company said Monday.

Par announced the shipment of amlodipine besylate and benazepril hydrochloride capsules in the 5-mg/320-mg and 10-mg/320-mg strengths. The drug is a generic version of Novartis’ Lotrel, which has annual sales of $361 million in the two strengths, according to IMS Health.

January 4, 2011

Generic drug maker Par Pharmaceutical has begun shipping its version of a treatment for heart rhythm problems, the company said Monday.

WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has begun shipping its version of a treatment for heart rhythm problems, the company said Monday.

Par announced the shipment of propafenone SR capsules, a treatment for atrial fibrillation in patients without structural heart disease.

The drug is a generic version of GlaxoSmithKline’s Rhythmol SR, which has annual sales of around $121 million, according to IMS Health.

December 20, 2010

The president of Par Pharmaceutical's subsidiary announced his resignation on Monday.

WOODCLIFF LAKE, N.J. — The president of Par Pharmaceutical's subsidiary announced his resignation on Monday.

John MacPhee, who served as president of Strativa and Par EVP, will leave the company, effective Jan. 31, to pursue other interests.

Patrick LePore, Par's president, chairman and CEO, will assume day-to-day oversight of Strativa on an interim basis.

November 22, 2010

WOODCLIFF LAKE, N.J. Par Pharmaceutical has begun shipments of a generic treatment for asthma, the drug maker said Monday.

Par announced that it started shipping zafirlukast tablets in the 10-mg and 20-mg strengths. The drug is a generic version of AstraZeneca’s Accolate.

Accolate has sales of $50 million in the United States per year, according to IMS Health.

November 14, 2010

The world of generic drugs has a big year ahead of it. Actually, it has...

The world of generic drugs has a big year ahead of it. Actually, it has a few big years ahead of it. But 2011 in particular carries a certain symbolic value as the year in which Pfizer, the world’s biggest drug maker, loses control of its patent for the cholesterol-lowering drug Lipitor (atorvastatin calcium), the world’s top-selling drug.

October 4, 2010

The Food and Drug Administration has approved a generic treatment for cough and upper respiratory...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a generic treatment for cough and upper respiratory symptoms resulting from colds and allergies made by Par Pharmaceutical and Tris Pharma, Par said Tuesday.

The FDA approved hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension. The drug is a generic version of UCB’s Tussionex, which has annual sales of around $226 million, according to IMS Health.

 

July 22, 2010

Generic drug maker Par Pharmaceutical Cos. has appointed a former Roche executive to its board...

July 12, 2010

Generic drug maker Amneal Pharmaceuticals has appointed a former Par Pharmaceutical Cos. executive as chief...

June 30, 2010

Generic drug maker Par Pharmaceutical has launched a generic version of a drug used to...

June 3, 2010

Par Pharmaceutical's CFO and EVP Lawrence Kenyon has resigned, the generic drug maker said Friday....

January 11, 2009

Par Pharmaceutical Cos. had total sales of $291.9 million and $26.3 million in profit for...